Aptahem AB (publ) (APTA.ST) Research

Aptahem AB (publ) is a clinical-stage biotechnology company dedicated to creating aptamer-based pharmaceuticals aimed at treating acute, life-threatening medical conditions. Its flagship drug candidate, Apta-1, is currently in preclinical development, designed to reduce the mortality rate in sepsis patients by combating organ and tissue damage. The company has established partnerships with several academic institutions, notably through a consortium comprising Örebro University, Seattle Children's Research Institute, and University Health Network. Founded in 2014, Aptahem AB (publ) operates from its headquarters in Malmö, Sweden.

Market snapshot

Symbol
APTA.ST
Price
$0.62
Day change
-4.29%
Market cap
$10.8M
P/E ratio
-2.04x
52-week range
0.5-2.4
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • 2cureX AB (publ) (2CUREX.ST)
  • Chordate Medical Holding AB (publ) (CMH.ST)
  • Fluicell AB (publ) (FLUI.ST)
  • Guard Therapeutics International AB (publ) (GUARD.ST)
  • LIDDS AB (publ) (LIDDS.ST)
  • ODI Pharma AB (ODI.ST)
  • Prostatype Genomics AB (publ) (PROGEN.ST)
  • Quia Pharma AB (publ) (QUIA.ST)

Open Aptahem AB (publ) (APTA.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.